Rationale Several studies have suggested that nicotine treatment can modulate the behavioral and neurochemical responses to other psychostimulants, such as cocaine. Objectives The current study examined the hypothesis that nicotinic acetylcholine receptor (nAChR) blockade influences the ability of cocaine to elicit increases in extracellular dopamine levels. Materials and methods Pharmacological studies using nicotinic antagonists as well as genetic inactivation of β2* nAChRs were used to determine the effect of nAChR blockade on dopamine levels in ventral striatum elicited by acute or repeated administrations of cocaine in mice. Results Administration of mecamylamine (a general nicotinic antagonist that is not highly selective for individual nAChR subtypes) or co-administration of methyllycaconitine (a more selective antagonist of α7* nAChRs) with dihydro-β-erythroidine (a more selective antagonist of β2* nAChRs and other heteromeric nAChR subtypes) prevented sensitization of cocaine-elicited increases in extracellular DA levels in the ventral striatum in wild-type mice. In contrast, neither of the more specific antagonists alone was effective in preventing sensitization. Finally, methyllycaconitine administration prevents sensitization in β2−/− mice but not in β2+/+ or wild-type mice. Conclusions These data indicate that inhibition of both α7* and β2* nAChRs is necessary to prevent development of sensitization of cocaine-elicited increases in extracellular dopamine levels in the ventral striatum of mice.
Introduction
Epidemiological evidence indicates that cigarette smoking and cocaine addiction are positively correlated (Budney et al. 1993) . Indeed, cigarette smoking has been considered a kind of "gateway" to other forms of drug abuse in adolescents (Lindsay and Rainey 1997) . It is likely that nicotine, acting through nicotinic acetylcholine receptors (nAChR), is one of the constituents in tobacco smoke that can influence cocaine addiction. Accordingly, it has been shown that nicotine treatment is able to modulate cocaine reinforcement in human subjects as well as in animal models. In smokers, an acute dose of nicotine can trigger cocaine craving, whereas a nicotinic antagonist can block cue-induced craving for cocaine (Reid et al. 1998 (Reid et al. , 1999 . In rodents, nicotine treatment induces increased self-administration of cocaine (Horger et al. 1992 ) and facilitates relapse to cocaine (Bechtholt and Mark 2002) . In addition, administration of the centrally acting nAChR antagonist mecamylamine or lack of β2* nAChRs decreased sensitivity to cocaine in a place preference paradigm (Zachariou et al. 2001) , while mecamylamine or MRZ 2/621 (a nAChR antagonist) pre-treatment dose-dependently decreased cocaine self-administration (Levin et al. 2000; Blokhina et al. 2005) .
One possible site for nicotine-cocaine interaction is the development of behavioral sensitization to cocaine, a phenomenon which is thought to contribute to the establishment of dependence to cocaine and other psychostimulants (Balfour et al. 1998; Vanderschuren and Kalivas 2000) . It has been shown that repeated exposures to nicotine enhance behavioral sensitization to amphetamine (de Rover et al. 2004) , while blockade of nAChRs prevents the induction of behavioral sensitization to amphetamine or cocaine (Schoffelmeer et al. 2002) .
Similar to most drugs of abuse, cocaine and nicotine share the ability to increase levels of extracellular dopamine (DA) in the ventral striatum (Dani and Heinemann 1996; Koob and Nestler 1997; Balfour 2002; Di Chiara et al. 2004) . It is, therefore, possible that interaction of these drugs occurs at this common target. The aim of this paper was to test the possibility that nAChR blockade influences the increase in extracellular DA elicited by cocaine. Therefore, we studied the effects of nAChR antagonists or genetic inactivation of β2* nAChRs on DA levels in ventral striatum elicited by acute or repeated administrations of cocaine in mice.
Materials and methods

Animals
Ten to 15-week-old male wild-type C57Bl/6 (Charles River, Calco, Italy) and β2+/+ mice and β2 knockout (β2−/−) mice were used. β2+/+ and β2−/− mice were the product of heterozygous matings and were backcrossed more than 12 generations onto the C57Bl/6 background. Mice were housed in groups of eight in clear plastic cages and maintained in a temperature-and humidity-controlled room on a 12-h light/dark schedule with food and water provided ad libitum. All animal experimentations were conducted in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC).
Drugs and treatments
All drugs used were purchased from Sigma. Cocaine hydrochloride (5-30 mg/kg, as salt), mecamylamine hydrochloride (1 mg/kg, as salt), methyllycaconitine citrate salt (MLA; 5 mg/kg, as salt) and dihybro-β-erythroidine hydrobromide (DHβE; 2.5 mg/kg, as salt) were administered intraperitoneally (i.p.). The doses of the nAChR antagonists used in this study were chosen on the basis of their efficacy in previous in vivo experiments in mice (for mecamylamine, see Stolerman et al. 1999; Zachariou et al. 2001; Blokhina et al. 2005; Grabus et al. 2006 ; for DHβE, see Gommans et al. 2000; Grabus et al. 2006 ; for MLA, see Damaj et al. 1999; Sher E, personal communication) .
In experiments involving acute cocaine administration, cocaine and nicotinic antagonists were co-administered. In experiments involving repeated cocaine administrations, the animals were treated either with cocaine (with or without the nAChR antagonist) or saline for 5 days. Cocaine (±nAChR antagonist) was injected on days 1, 3, and 5, and the animal was placed in the cage where the microdialysis experiment was to be performed. Saline was injected on days 2 and 4 and the animal remained in its home cage. On day 5, drug treatment was followed by a microdialysis experiment. This protocol was designed to mimic a place preference paradigm as closely as possible (see Zachariou et al. 2001) . To test the effects of injections and cage pairing, we treated a group of animals with saline for 5 days. After the injections, the animal was placed in the microdialysis cage on days 1, 3, and 5 and in the home cage on days 2 and 4. On day 5, saline treatment was followed by the microdialysis experiment.
Microdialysis procedure
Mice were anesthetized with halothane (Fluothane) and placed in a flat skull position in a Kopf stereotaxic apparatus fitted with a mouse adaptor. A microdialysis probe (CMA 7/2, 2 mm dialysis membrane, Carnegie Medicine, Stockholm, Sweden) was inserted through a guide cannula into the right striatum at the following coordinates: AP=+0.8 mm, DV=−3.8 mm, L=−1.5 mm, as reported in Picciotto et al. 1998 . The guide cannula was permanently secured with epoxy glue. After surgery, the mice were placed in a circular Plexiglas cage and recovered overnight before the microdialysis experiment (acute experiments) or before the first cocaine or saline treatment (repeated experiments). The inlet tubing of the probe was connected to a microinjection pump (CMA/100, Carnegie Medicine, Stockholm, Sweden) and perfused with artificial cerebrospinal fluid (aCSF: KCl 2.5 mM, NaCl 125 mM, CaCl 2 1.26 mM, MgCl 2 1.18 mM, Na 2 HPO 4 2 mM, pH 7.4) at a flow rate of 1.1 μl/min (22 μl/20-min sample). At the end of each experiment, the brain was removed from the skull, and the position of the microdialysis probe was verified by sectioning on a cryostat and microscopic examination.
Detection of dopamine
A volume of 20 μl from each sample was injected into a HPLC system with electrochemical detection for determination of DA concentrations (ESA coulometric detector with a 5014 B cell, voltage: E1=−150 mV; E2: +220 mV (Coulochem II Electrochemical Detector). Separation of DA was performed on a ESA HR-80 column (80×4.6 mm I.D.). The mobile phase consisted of 20% methanol in 75 mM NaH 2 PO 4 , 1 mM 1-octanesulfonic acid (sodium octane sulphonate), and 20 μM EDTA (pH 5.6). The flow rate was 1.0 ml/min (ESA Model 580 Solvent Delivery Module). The chromatograms were integrated using ESA CDS V3.0 HPLC Software. DA detection limit was 5 fmol/ sample and baseline DA concentration was 20-30 fmol/ sample.
Statistical analysis
All results are expressed as mean±standard error of the mean (S.E.M.), comparisons among groups were performed using one-way or repeated measures analysis of variance (ANOVA), followed by post-hoc Bonferroni's test for multiple comparisons.
Results
A preliminary dose-response curve for the effects of cocaine on DA perfusate levels in the ventral striatum was performed in wild-type mice. Cocaine at the dose of 5, 10, and 30 mg/kg i.p. elicited significant increases of perfusate DA levels over basal levels (peak effect, 20 min after cocaine administration) by 31±8 (n=9, repeated measures ANOVA, F(1, 13)=9.71, p=0.008), 82±39 (n=6, repeated measures ANOVA, F(1, 10)=9.26, p=0.012) and 191±92% (n=6, repeated measures ANOVA, F(1, 10)=57.90, p<0.001), respectively ( Fig. 1) . The 5 mg/kg dose of cocaine has been reported as a threshold dose for cocaine place preference in C57Bl/6 mice (Zachariou et al. 2001) and was used in all further experiments.
We first studied the effects of the peripheral coadministration of mecamylamine (1 mg/kg, i.p.) and cocaine on DA perfusate levels from the ventral striatum (Fig. 2) . While no significant difference in either overall effect (repeated measures ANOVA, F(1, 24)=2.36, NS) or peak effect was observed between acute cocaine (n=12) and acute cocaine+mecamylamine (n=14) treatment, a modest prolongation of the increase in DA perfusate levels (oneway ANOVA, third time post-treatment F(1, 24)=4.00, p=0.057, fourth time post-treatment F(1, 24)=5.19, p=0.032) was observed. When mecamylamine (n=6) was administered alone, there was no significant change in DA perfusate levels with respect to vehicle (n=6) administration (Fig. 2) .
Another set of animals was treated with cocaine three times, once every other day, pairing each treatment with the cage where the microdialysis experiment was to be performed to mimic a place preference paradigm (Zachariou et al. 2001) . Following this regimen of administration, sensitization of the DA response to repeated cocaine treatments was observed as measured by a significant Fig. 1 Dose-response curve of changes in DA perfusate levels in ventral striatum of wild-type mice elicited by a single-cocaine i.p. administration. Statistical analysis comparing the global effects of cocaine treatments by repeated measures ANOVA. 5 mg (n=9) vs saline (n=6), F(1, 13)=9.71, p=0.008), 10 mg (n=6) vs saline, F(1, 10)=9.26, p=0.012, 30 mg (n=6) vs saline, F(1, 10)=57.90, p<0.001) Fig. 2 Effects of mecamylamine (1 mg/kg, i.p.) on the increase in DA perfusate levels from the ventral striatum of wild-type mice elicited by acute cocaine treatment (5 mg/kg). Statistical analysis comparing the global effect of cocaine treatment with or without mecamylamine was performed by repeated measures ANOVA, F(1, 24)=2.36, NS; single time points were compared by one-way ANOVA; *: p<0.05; +: p<0.10. Group size: saline=6, mecamylamine=6, cocaine+saline=12, cocaine+mecamylamine=14 augmentation of the peak increase in DA perfusate levels 20 min after the final cocaine challenge with respect to a single cocaine administration. This increase was significantly counteracted by repeated cocaine+mecamylamine co-treatments ( Fig. 3a and b ; one way ANOVA on peak effect, F(3, 36)=7.51, p<0.001, post hoc Bonferroni's test: repeated cocaine+cocaine challenge (n=15) vs repeated cocaine/mecamylamine+cocaine/mecamylamine challenge (n=8), p=0.044 vs acute cocaine (n=8), p=0.038 vs repeated cocaine+saline challenge (n=9), p<0.001).
As a control, we also performed a treatment with saline, paired twice every other day with the cage where the microdialysis experiment was to be performed. We then challenged the animals with cocaine (n=8) or saline (n=6) on the fifth day. Cocaine induced a significant peak increase by about 30% in DA extracellular levels with respect to saline treatment (Fig. 4) , one-way ANOVA, F(1, 12)=150.56, p<0.001), a peak increase that is very similar to that of acute cocaine treatment. These results show that simple pairing of the animals with the microdialysis cage does not cause a sensitization of DA response to a cocaine challenge.
In an attempt to identify the nAChR subtype(s) responsible for the effects of mecamylamine, a nonselective nAChR antagonist, on sensitization of the DA response to repeated cocaine treatments, we coupled administration of the α7* nAChR-selective antagonist MLA (5 mg/kg, i.p.) and/or the selective β2* nAChRselective antagonist DHβE (2.5 mg/kg, i.p., Harvey et al. 1996; Whiteaker et al. 2000) with cocaine administration in the sensitization protocol described above. The two nAChR antagonists were ineffective when each of them was coadministered with cocaine, but were able to significantly counteract the peak increase in DA perfusate levels elicited by repeated cocaine treatment when both antagonists were co-administered with cocaine ( Fig. 5a and b ; one-way ANOVA, F(3, 27)=6.38, p=0.002; post-hoc Bonferroni's test: repeated cocaine+cocaine challenge (n=10) vs repeated cocaine/DHβE/MLA+cocaine/DHβE/MLA challenge (n=7), p=0.004, repeated cocaine/MLA+cocaine/MLA challenge (n=7), NS, repeated cocaine/DHβE+cocaine/ DHβE challenge (n=7), NS).
To confirm the data obtained on wild-type C57Bl/6 mice, we performed the cocaine sensitization protocol in β2−/−mice in the presence or absence of nAChR antagonist pretreatment. In accordance with previous studies , basal DA perfusate levels did not differ between β2+/+ (1.74±0.30 nM, n=4) and β2−/− (1.78±0.33 nM, n=5) mice. Repeated cocaine treatments elicited a peak increase in DA perfusate levels by Fig. 3 Effects of mecamylamine (MECA, 1 mg/kg, i.p.) on cocaine (coc, 5 mg/kg)-elicited increase in DA perfusate levels from the ventral striatum of wild-type mice treated with repeated cocaine administration. a Time course of the effects. b Comparison of peak effects. Statistical analysis comparing the peak effects was performed by one-way ANOVA, F(3, 36)=7.51, p<0.001; post hoc Bonferroni's test: repeated coc+coc challenge (n=15) vs repeated coc/MECA+coc/ MECA challenge (n=8) p=0.044, vs acute coc (n=8) p=0.038, vs repeated coc+saline challenge (n=9) p<0.001 Fig. 4 Cocaine (5 mg/kg) elicited increase in DA perfusate levels from the ventral striatum of wild-type mice treated with repeated saline administration. Statistical analysis comparing the peak effect of repeated saline+cocaine challenge (n=8) vs repeated saline+saline challenge (n=6) by one-way ANOVA, F(1, 12)=150.56, p<0.001 about 90% in both β2+/+ and β2−/− mice (one-way ANOVA, β2+/+ vs β2−/−, NS, not shown). We then tested whether mecamylamine inhibition of cocaine sensitization of DA release was preserved in β2−/−mice and examined the effect of the α7* nAChR-selective antagonist MLA in this paradigm. Both repeated cocaine+mecamylamine and cocaine+MLA co-treatments were able to significantly counteract the augmentation in the peak of cocaine-elicited increase in DA perfusate level present in β2−/− mice treated by repeated cocaine administration ( Fig. 6a and b ; one-way ANOVA for peak effect,F(2, 16)=14.744, p<0.001; Bonferroni's test: repeated cocaine+saline challenge (n=5) vs repeated cocaine/mecamylamine+cocaine/ mecamylamine challenge (n=7), p<0.001 vs repeated cocaine/MLA+cocaine/MLA challenge (n=7), p=0.002).
Discussion
Epidemiological evidence and previous studies in animal models suggest that nicotine can potentiate cocaine reinforcement and addiction. As both nicotine and cocaine administration result in increased extracellular DA levels in the ventral striatum, it has been hypothesized that nicotinecocaine interactions may be mediated through this mechanism. The experiments described in this paper support this hypothesis and show that inhibition of nAChRs modulates cocaine-elicited DA release differentially in cocaine-naive vs cocaine-pretreated mice. In naive mice, co-administration of cocaine and mecamylamine results in a modest potentiation of acute cocaineelicited increases of DA extracellular levels in the ventral striatum. One potential mechanism for this effect is that mecamylamine can antagonize nAChRs expressed by GABA neurons in the VTA or ventral striatum. Acute treatment with nicotine can stimulate GABA release in these brain areas (Erhardt et al. 2002; Mansvelder et al. 2002 Mansvelder et al. , 2003 , which in turn may inhibit cocaine effects (Dewey et al. 1997; Fadda et al. 2003) . Thus, acute coadministration of cocaine and nicotinic antagonists may result in a decrease in GABAergic tone in the mesolimbic DA pathway that potentiates acute effects of cocaine on DA overflow.
After repeated exposures, cocaine-induced behavioral sensitization is paralleled by increased responsiveness of the mesolimbic DA system to cocaine challenge (Vanderschuren and Kalivas 2000) . Accordingly, in the current experiments, repeated cocaine treatments of mice over 3 alternate days induced an increased DA response to cocaine challenge. This demonstrates that a treatment regimen, which is currently used for place preference conditioning (Zachariou et al. 2001) , leads to sensitization of cocaine-induced extracellular DA levels. Co-treatment with mecamylamine abolished the increase in DA response to cocaine challenge, indicating that nAChR activation is necessary to develop cocaine-induced sensitization of the DA response to cocaine challenge. Mecamylamine treatment is also able to block cocaine-induced behavioral sensitization (Schoffelmeer et al. 2002) as well as cocaine place preference (Zachariou et al. 2001 ). Although other hypotheses are possible (e.g., that mecamylamine interferes with postsynaptic targets of DA, Nestler 2001), a distinct possibility is that decreased DA response to cocaine challenge induced by decreased nAChR activity contributes to both these behavioral events.
Further experiments using the same sensitization paradigm showed that co-administration of MLA (α7* nAChRselective antagonist), along with DHβE (β2* nAChR selective antagonist), but not the administration of either of the two antagonists alone, could mimic the effects of mecamylamine on sensitization of the cocaine-elicited increase in extracellular DA levels in the ventral striatum. These data suggest that activation of either nAChR subtype is sufficient for the development of cocaine sensitization.
To confirm and further characterize the nAChR subtype (s) responsible for the modulation of cocaine sensitization of the DA response to cocaine challenge, we used the protocol of repeated cocaine treatment and challenge in β2−/− mice and control β2+/+ mice. β2−/− mice lack high affinity binding for nicotinic agonists in the ventral midbrain and striatum as well as heteromeric receptor-type electrophysiological responses in DA midbrain neurons Champtiaux et al. 2003) but do not show alterations in α-bungarotoxin binding (a marker of α7* nAChRs in rodent brain; in mesostriatal regions or α7* nAChR electrophysiological responses in DA midbrain neurons (Klink et al. 2001; Champtiaux et al. 2003) . The extent of increase in DA extracellular levels in ventral striatum elicited by cocaine challenge in mice treated with repeated cocaine did not differ in β2+/+ and β2−/− mice, indicating that β2* nAChRs alone are not responsible for nicotinic modulation of cocaine sensitization of DA release.
We then tested the effects of mecamylamine and MLA on extracellular DA levels in the striatum of β2−/− mice treated with repeated cocaine. Both nicotinic antagonists were able to effectively inhibit cocaine sensitization of DA response, indicating that MLA-sensitive nAChRs are responsible for this effect in β2−/− mice. Although MLA is often considered a selective antagonist for α7* nAChRs in rodents, it has been shown that in addition to an affinity for α7* nAChRs in the low nanomole (nM) range (Orr-Urtreger et al. 1997) , MLA can also bind α6β2* nAChRs in the high nM range (Mogg et al. 2002; Zoli et al. 2002) . Therefore, it is difficult, in general, to exclude that treatment with MLA does not influence other receptor subtypes, including α6β2* nAChRs. Yet, the fact that MLA is effective in β2−/− mice (which do not express α6β2* nAChRs) strongly supports the hypothesis that the inhibition of cocaine sensitization that we have observed depends on an action at α7* nAChRs.
The ability of an α7 antagonist to disrupt plasticity in the β2 knockout mice but not in wild-type mice suggests that α7 and β2 nAChRs may compensate for each other in other phenotypes in knockout mice lacking a single nAChR subunit as well, as has been recently shown for passive avoidance (Marubio and Paylor 2004) .
While the current experiments support the involvement of both α7* and β2* nAChRs in development of cocaine sensitization, the location of the nAChRs responsible for this effect remains unknown. β2* nAChRs are expressed in dendrites, cell bodies, and terminals of mesostriatal DA neurons, whereas α7* nAChRs are enriched only in the dendrite/cell body compartment (Zoli et al. 2002; Picciotto et al. 1998; Klink et al. 2001) . Other neuronal systems activated by cocaine and influencing its effects on the DA pathway may also express nAChRs. Future studies with local injections of the antagonists and selective lesions of pathways putatively involved in cocaine effects will help clarify this issue.
Overall, the present results strongly suggest that blockade of both α7* nAChRs and β2* nAChRs are necessary to prevent the sensitization of cocaine-elicited increase in DA extracellular levels in ventral striatum present in mice repeatedly treated with cocaine. These data imply that an endogenous cholinergic tone acting on either α7* or β2* nAChRs is necessary for the development of increased cocaine-elicited DA release after repeated cocaine treatment. This cholinergic tone can be either basal or induced by cocaine itself. In fact, it has been shown that cocaine affects acetylcholine turnover rates or release in several brain regions inducing changes that differ according to the type of treatment (passive acute or repeated injection or self-administration) and brain region considered (Imperato et al. 1993; Zocchi and Pert 1994; Day et al. 1997; Mark et al. 1999; Smith et al. 2004) . It can, therefore, be hypothesized that the different regimens of cocaine treatments themselves differentially alter the influence of the cholinergic inputs on cocaine cerebral targets and change the effects of systemic nAChR antagonists on cocaine effects.
